The landscape of public health in Europe is currently undergoing a seismic shift. As the tobacco industry evolves, moving rapidly from traditional combustible cigarettes to a sophisticated array of high-tech nicotine delivery systems, policymakers are scrambling to keep pace. At the heart of this struggle is a pivotal question: Can the European Union reform its legislative framework quickly enough to protect a new generation from the grip of lifelong addiction?
This urgent inquiry served as the focal point for the recent "Say No to Nicotine" summit. Organized by the European Respiratory Society (ERS) on behalf of the European Chronic Disease Alliance, the event brought together Members of the European Parliament (MEPs), representatives from the World Health Organization (WHO), and leading public health experts to debate the future of tobacco and nicotine regulation.
Main Facts: The Urgent Call for Regulatory Reform
The "Say No to Nicotine" event was not merely a forum for discussion; it was a rallying cry for the upcoming revision of the EU Tobacco Products Directive (TPD). The TPD, which serves as the cornerstone of EU-wide legislation governing tobacco and nicotine products, is widely regarded by experts as being in dire need of an update.
The primary concern is the current regulatory fragmentation. As it stands, national rules regarding marketing, sales, and product classification vary significantly across the EU’s member states. This lack of harmonization creates substantial loopholes that the tobacco industry is all too eager to exploit. From the proliferation of youth-appealing flavourings in e-cigarettes to the aggressive marketing of nicotine pouches, current directives are failing to address the realities of a market that has fundamentally changed in the last decade.
Experts at the summit highlighted that while the industry markets these new products as "adult-oriented" harm-reduction tools, the empirical data suggests otherwise. Usage rates among young people are climbing, raising the specter of a secondary wave of nicotine dependency—one that utilizes sleek, high-dose delivery systems that are often inadequately regulated by current health standards.
Chronology: A Decade of Evolving Risks
To understand the urgency of the current moment, one must look at the timeline of the tobacco industry’s evolution.
2014: The TPD Landmark
The current EU Tobacco Products Directive was adopted in 2014. At the time, it was hailed as a robust piece of legislation designed to curb the prevalence of traditional smoking. However, it was designed primarily for the market as it existed a decade ago, with only nascent provisions for emerging electronic nicotine delivery systems.
2016–2020: The Digital Marketing Surge
During this period, the industry shifted its focus toward the "next generation" of products. The rise of influencer marketing and social media-based campaigns made nicotine products appear not as hazardous health risks, but as lifestyle accessories. Regulatory bodies were slow to pivot to these digital platforms.
2022–2023: The Rise of Nicotine Pouches
The market witnessed a massive influx of nicotine pouches—small, discrete sachets that provide high doses of nicotine without the need for inhalation. Because these products often fall outside the definition of "tobacco," they bypassed many of the strict regulations governing traditional cigarettes.
2024–2025: The "Say No to Nicotine" Initiative
Recognizing the widening gap between product innovation and legislative oversight, organizations like the ERS and the European Lung Foundation (ELF) ramped up advocacy efforts. The "Say No to Nicotine" event marks the current crescendo of this effort, positioning the upcoming TPD revision as a "do-or-die" moment for European public health.
Supporting Data: The Hidden Cost of Innovation
The data presented at the summit paints a sobering picture. Dr. Daniëlle Cohen of the Leiden University Medical Centre emphasized that the health impact of high-dose nicotine is not merely a matter of traditional addiction; it is a complex physiological concern.
Current research suggests that high-dose nicotine exposure in adolescents can have long-lasting effects on brain development, cognitive function, and cardiovascular health. Despite this, the market is saturated with products that contain higher nicotine concentrations than those traditionally found in combustible cigarettes.
Furthermore, the "gateway effect" remains a central point of contention. While industry advocates argue that e-cigarettes are a bridge to cessation for long-term smokers, public health data suggests they are frequently becoming the entry point for non-smoking youth. The accessibility of these products, combined with the lack of standardized age-verification processes across all EU member states, creates a regulatory "wild west."
Official Responses: The Call for Decisive Action
The voices at the "Say No to Nicotine" summit were unified in their call for systemic change.
Dr. Filippos Filippidis, Chair of the ERS Tobacco Control Committee, did not mince words regarding the industry’s role. "Young people are being targeted by the powerful tobacco industry, which continues to promote its harmful and addictive tobacco and nicotine products," he stated. "We are at a crucial time for public health in Europe. We need to ensure that EU directives provide adequate protection for future generations. We know what works; implementing evidence-based policies can prevent nicotine addiction and millions of deaths."
Dr. Angela Ciobanu of WHO Europe mirrored this sentiment, framing the issue as an existential challenge for the continent. "The question is no longer whether nicotine and tobacco products are evolving," she noted. "The question is whether public health policies can keep pace. Europe has an opportunity to take the lead in preventing a new generation from becoming addicted to nicotine."
A notable highlight of the event was the discussion surrounding the UK’s proposed generational ban. Zena Powell, a patient representative from the ELF Council, noted that this approach—which would effectively prevent anyone born after a certain date from ever legally purchasing tobacco—generated significant interest among policymakers. "It was encouraging to hear discussions on future-proofing legislation," Powell said. "The UK’s generational ban stood out as a bold and innovative approach to tobacco control."
The Role of the Patient Voice
A recurring theme throughout the summit was the necessity of integrating the patient perspective into the policy-making process. The European Lung Foundation (ELF) has made this a central pillar of its advocacy. By involving members of its Youth Group and the ELF Council, the organization ensures that the lived experience of those affected by respiratory disease is not lost in the abstract legal discussions of the European Parliament.
Patient participation is not merely symbolic; it is essential for identifying where existing policies fail to account for the day-to-day realities of lung health. When a policy is designed in a vacuum, it often ignores the practicalities of addiction management and the long-term, debilitating impact of lung conditions. By bridging the gap between clinical data and patient advocacy, the ELF and its partners provide a more holistic understanding of why the TPD revision must be as comprehensive as possible.
Implications: A New Era for EU Health Policy
The implications of the upcoming TPD revision are vast. If the EU moves to harmonize regulations—implementing strict bans on youth-appealing flavours, capping nicotine concentrations, and mandating uniform marketing restrictions—it could set a global standard for tobacco control.
However, the road ahead is fraught with political and economic hurdles. The tobacco industry remains one of the most powerful lobbying forces in Brussels. The challenge for MEPs will be to prioritize the long-term health of the European citizenry over the short-term economic interests of the nicotine market.
The "Say No to Nicotine" event served as a clarion call. It demonstrated that the tools for prevention are available, but they require the political will to be implemented. From the adoption of generational bans to the regulation of high-dose nicotine pouches, the EU stands at a threshold.
As Dr. Filippidis aptly concluded, the focus must shift from merely "managing" tobacco use to actively preventing it. If the European Union fails to close these regulatory gaps now, it risks presiding over a new, preventable epidemic of addiction. The message to the European Parliament is clear: the time for incremental change has passed; the time for bold, evidence-based, and future-proofed regulation is now.
Through the ongoing efforts of the ERS, the WHO, and patient-led organizations like the ELF, the conversation has moved from the sidelines to the center of the EU’s legislative agenda. The outcome of the TPD revision will ultimately determine whether Europe becomes a leader in protecting the health of its youth, or whether it allows a new generation to fall victim to the oldest of traps.
